title: Pathophysiology of GHRH-growth hormone-IGF1 axis in HIV/AIDS.
abstract: Aberrations in GHRH-GH -IGF-I axis are common in the complex of HIV, HAART and AIDS. There are 2 distinct mechanisms at play in HIV and AIDS. One is primarly associated with development of lipodystrophy and results in complications such as chronic inflammation, insulin resistance, lipid and metabolic abnormalities. HIV lipodystrophy is found especially in those on highly active anti-retroviral therapy (HAART). The various processes involved in lipodystrophy result in the suppression of pituitary GH production. The mechanism of low GH levels relates to increased somatostatin tone, decreased Ghrelin, increased free fatty acids (FFA) and insulin resistance. On the other hand in AIDS wasting syndrome; elevated GH and low IGF-1 levels are seen suggesting GH resistance. The GHRH analog-Tesamorelin is the only treatment option, which is FDA approved for use in reduction of excess abdominal fat in patients with HIV-associated lipodystrophy. Although long-term clinical trials and experience is needed to further study the benefits and risks of Tesamorelin.
authors: Department of Pediatrics, SUNY Downstate Medical Center & Kings County Hospital Center, Brooklyn, NY 11203, USA.
authors: Shobhit
authors: S
authors: Jain
authors: Ninad
authors: N
authors: Desai
authors: Amrit
authors: A
authors: Bhangoo
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000378:metabolism* / Q000503:physiopathology*; D013006:Growth Hormone / Q000378:metabolism; D013007:Growth Hormone-Releasing Hormone / Q000378:metabolism*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D008060:Lipodystrophy / Q000378:metabolism; D008954:Models, Biological
chemical_list: D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone
references: JAMA. 2002 Jul 10;288(2):207-15
references: 12095385
references: AIDS. 2005 Jun 10;19(9):917-25
references: 15905672
references: Am J Physiol. 1997 Jun;272(6 Pt 1):E1108-16
references: 9227458
references: Clin Endocrinol (Oxf). 1996 May;44(5):501-14
references: 8762726
references: Neuroendocrinology. 1991 Feb;53(2):185-9
references: 1673023
references: J Endocrinol Invest. 2008 Sep;31(9 Suppl):33-8
references: 19020383
references: J Clin Invest. 1997 Oct 15;100(8):2125-32
references: 9329979
references: J Clin Endocrinol Metab. 2001 Nov;86(11):5509-15
references: 11701729
references: J Clin Endocrinol Metab. 1996 Nov;81(11):4028-32
references: 8923855
references: J Acquir Immune Defic Syndr. 2005 May 1;39(1):44-54
references: 15851913
references: J Clin Endocrinol Metab. 2001 Aug;86(8):3845-52
references: 11502822
references: Cytokine. 2006 Apr;34(1-2):51-5
references: 16697654
references: HIV Med. 2003 Jul;4(3):293-301
references: 12859330
references: Biochim Biophys Acta. 1997 Oct 23;1329(2):269-77
references: 9371418
references: Scand J Infect Dis. 2004;36(11-12):832-9
references: 15764170
references: HIV Clin Trials. 2008 Jul-Aug;9(4):254-68
references: 18753120
references: J Clin Endocrinol Metab. 2007 Jun;92(6):2336-45
references: 17405836
references: J Clin Endocrinol Metab. 2001 Feb;86(2):504-10
references: 11158000
references: J Clin Endocrinol Metab. 1998 Dec;83(12):4251-6
references: 9851759
references: AIDS. 2006 Oct 24;20(16):2043-50
references: 17053350